177Lu-NYM096 / Peking Union Medical College, Norroy Biosci - LARVOL DELTA

Preclinical and First-in-Human Study of Carbonic Anhydrase IX-Targeting Theranostic Pair, [68Ga]Ga/[177Lu]Lu-NYM096, in Clear Cell Renal Cell Carcinoma. (PubMed, J Nucl Med) - " This is early evidence that the CAIX-targeting theranostic pair [68Ga]Ga/[177Lu]Lu-NYM096 is feasible, offering a strategy for patients with end-stage ccRCC. The gastric toxicity proposes a significant challenge for CAIX-targeting radiopharmaceutical therapy."

First-in-human • Journal • P1 data • Preclinical • Clear Cell Renal Cell Carcinoma • Gastrointestinal Disorder • Genito-urinary Cancer • Hematological Disorders • Oncology • Solid Tumor • CA9

NYCRRLT: 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC (clinicaltrials.gov) - P1 | N=20 | Suspended | Sponsor: Peking Union Medical College Hospital | Recruiting ➔ Suspended

Trial suspension • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Very first experience with 68Ga/177Lu-NYM096 in patients with metastatic clear cell renal cell carcinoma (SNMMI 2025) - P1 | "Purpose/Background: NYM096 is a new-generation carbonic anhydrase 9 (CA9) targeting small molecule that can be labeled with both 68Ga and 177Lu. One patient with metastatic ccRCC, aged 61 years, was enrolled. The patient had progressive disease after 2 lines of treatment (1st line, axitinib plus pembrolizumab, 2nd line, lenvatinib plus pembrolizumab). 68Ga-NYM096 PET/CT (Figure 1) demonstrated multiple CA9-positive metastases involving lung, pleural, LN, bone, soft tissue, and thyroid."

Clinical • IO biomarker • Metastases • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor • CA9